Amgen, biotech drug developer, said it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that generated more than $1 billion in its first full year on the market.
The deal offers Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs.
Horizon Therapeutics PLC, based in Dublin, Ireland, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.
Read more at Associated Press
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.